Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Science ShareTwitterFacebookXingLinkedin AppetiteGhrelinGhrelin-O-acyltransferasepharmacodynamicspharmacokineticstolerability You May Also Like Science 25. Mai 2023 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Science 25. Mai 2023 (Bersacapavir) In Participants With Moderate Hepatic Impairment. Science 25. Mai 2023 Discordance between estimated and measured changes in plasma volume among patients with acute heart failure.